Q2 2026 Earnings Summary Briefing for the Fiscal Year Ending December 2026 – Q&A (Highlights) Transcript

Key points of performance

In the Q&A of this earnings briefing, discussions focused on the profitability and scope of the AI-related new service “AI Home-Visit Nursing Scoring,” the expected billing at period-end, and how it is incorporated into mid-term plans. Revenue contribution from the new service is not yet reflected in the mid-term plan, while development costs are included, implying margin upside if actual performance exceeds expectations. NRR stands at 108.0%, with a goal to exceed 110% going forward. Approximately 400 ending contracts; 246 cases starting in July are largely with existing customers, and the pricing framework is assumed to include a monthly fee of 15,000 yen plus 100 yen per usage unit.

Growth strategy and capital allocation

Aiming for long-term expansion centered on iBow within the domestic home medical care space. In the mid-to-long term, we aim to enable information sharing in chronic-phase medical care, prioritizing investment in AI development and customer success structure. Revenue target is over 6.0 billion yen in 2028 and 50% market share by 2040. Cash on hand will be prudently utilized within a capital policy including growth investment and potential M&A.